Have a Claim?

Click here for a confidential contact or call:

1-347-417-2192

Medical Lab to Pay Over $20 Million to Resolve False Claims Act Claims for Allegedly Retaining Overpayments from Federal Agency

Posted  October 22, 2026

By the Constantine LLP Whistleblower Team

Signal Diagnostics LLC (“Signal”), a clinical medical laboratory, recently agreed to pay the government over $20.5 million to settle False Claims Act claims alleging that it submitted false claims to the Health Resources & Services Administration (“HRSA”), a U.S. Department of Health and Human Services agency, and that it knowingly avoided the obligation to repay those overpayments.[1]

What Federal Program Was Involved?

This case involved the HRSA’s “COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program,” referred to as the “UIP.”

In response to the COVID-19 pandemic, the UIP reimbursed health care providers for COVID-19 testing, treatment, and vaccination services provided to uninsured patients who “did not have any health care coverage at the time services were rendered.”[2]  Reimbursements through the UIP were “generally at Medicare rates, subject to available funding.”[3]

What Were the Allegations Against Signal?

In this case, according to the DOJ, Signal submitted claims to the UIP for COVID-19 testing services and specimen collection between October 2020 and March 2022.  The DOJ alleged that Signal “conducted an internal audit” and “determined that it had submitted claims to the UIP that were ineligible for payment because the individuals had insurance.”[4]  In particular, the audit allegedly identified “errors that caused the submission of claims to the UIP for people who had insurance, including instances where Signal’s internal system had created multiple profiles for the same individuals with conflicting insurance information, and claims were submitted to the UIP when there were alternative insurances listed on file.”[5]  According to the DOJ’s allegations, Signal went so far as to “calculate[] the amount of overpayment that it had received from the UIP for ineligible claims,” yet it “knowingly and improperly avoided its obligation to repay HRSA for overpayments reimbursed to it from the UIP.”[6]

While not admitting liability, Signal agreed to pay the United States $20,594,640.13 to settle the claims.[7]  Notably, although the DOJ alleged that Signal knowingly avoided the obligation to repay the overpayments, under the Settlement Agreement Signal was “credited $7,956,936.89 towards the Settlement Amount for previous refund payments made by Signal to the United States.”[8]

Federal Enforcers’ Comments on the Case

DOJ Assistant Attorney General Brett A. Shumate commented: “When companies knowingly retain federal healthcare program funds they were not entitled to receive, they violate the public’s trust and the law. Today’s settlement reflects our commitment to protecting taxpayer dollars and ensuring that providers meet their obligations to return money to which they were not entitled.”[9]

Acting Deputy Inspector General for Investigations of the U.S. Department of Health and Human Services Office of Inspector General, Miranda Bennett, echoed the warning to health care providers: “Providers who receive federal program funds must meet their legal obligation to return money they are not entitled to.  By knowingly avoiding repayment of overpayments, Signal Diagnostics undermined the integrity of a program designed to support uninsured patients during a national public health emergency.  HHS-OIG will continue to work closely with our law enforcement partners to ensure that entities that misuse federal health care dollars are held fully accountable.”[10]

How Can Whistleblowers Help Fight Fraud?

Failing to timely repay known overpayments from the government is a common fact pattern in False Claims Act cases.  Constantine LLP partner Marlene Koury commented, “Whistleblowers play a vital role in uncovering health care fraud, which drains government funds from important programs designed to help patients.”  “Many times, fraudulent schemes are conducted in secret,” Koury added, “and whistleblowers are in the best position to bring the misconduct to light.”

The False Claims Act serves an important function by encouraging whistleblowers to come forward and report fraud against the government, awarding whistleblowers up to 30% of a successful recovery.

Speak Confidentially With Our Whistleblower Attorneys

[1] https://www.justice.gov/opa/media/1463491/dl (press release).

[2] Id.; https://www.hrsa.gov/provider-relief/about/covid-uninsured-claim/faq (HRSA FAQ)

[3] https://www.hrsa.gov/provider-relief/about/covid-uninsured-claim/faq (HRSA FAQ).

[4] https://www.justice.gov/opa/media/1463491/dl (Settlement Agreement).

[5] Id.

[6] Id.

[7] Id.

[8] Id.

[9] https://www.justice.gov/opa/pr/signal-diagnostics-agrees-pay-over-20m-settle-false-claims-act-allegations-failing-refund (Press Release).

[10] Id.

Tagged in: COVID-19, False Claims Act,


Constantine Cannon is now Constantine LLP